Cohort, Custodian Property Income REIT, Pathfinder Minerals Plc and Verici Dx

Join Shares and AJ Bell for an evening of investment inspiration and get to meet the decision-makers.

The event on Wednesday 17 July in London will include:

• An opportunity for you to talk directly with the directors and ask your questions about the companies’ core strengths and their short and long-term business strategy

• Meet fellow investors and share your investing experience

• Complimentary drinks and snacks

More about the companies presenting:

Cohort (AIM: CHRT) is the parent company of six innovative, agile and responsive defence technology businesses providing a wide range of services and products for UK and international customers. It has headquarters in Reading, Berkshire and employs in total over 1,100 core staff there and at its other operating company sites across the UK, Germany, and Portugal. Cohort was admitted to London's Alternative Investment Market in March 2006.

Custodian Property Income REIT (CREI) offers investors the opportunity to access a diversified portfolio of UK commercial real estate through a closed-ended fund that seeks to provide an attractive level of income and the potential for capital growth

Pathfinder Minerals Plc (PFP) is a natural resources company, seeking to mine heavy mineral sands in countries that include Mozambique and Cameroon, and pursue opportunities in battery metals projects in countries including Zimbabwe, Madagascar,and Malawi. The firm has a license to mine land on the Indian Ocean coast of Zambezia province of Mozambique. It is looking for heavy minerals such as ilmenite, rutile, and zircon, which are used in the manufacture of products across the industrial sectors.

Verici Dx (VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence (AI) assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.

*Please note this is not the order of the presentations

The evening is a perfect opportunity for existing shareholders or potential investors to hear from the directors running the companies to explain their strategy and opportunity for investors and meet them over drinks after their presentations.